Clinical trials: Neoplasia Prostate
Adverse Reaction to Diagnostic Agents and Kits Nos
Tracking Peripheral Blood Mononuclear Cells With Fluorine MRI
Cell-based therapies in the form of stem cell-based or immune cell-based therapies are becoming important treatment options that are either approved for clinical use or are showing promise in clinical trials.
- Trial name
- TRACK (NCT02921373)
- Testing
- 19F Cell Sense-labeled PBMC, MRI
- Where
- Canada
- Volunteers
- healthy volunteers welcome
- Sponsor
- Gregory A. Dekaban
Prostate Cancer
Multispectral Fluorescence as a Tool to Separate Healthy and Disease Related Lymphatic Anatomies in Prostate Cancer.
Multispectral imaging of the lymphatic draining pattern of the tumor and the abdominall wall/lower limb to evaluate technical feasibility to differentiate these patterns and in the future reduce the amount of complications that…
- Trial name
- SPLIT (NCT05120973)
- Testing
- multispectral imaging, fluorescence for lymphatic mapping
- Where
- Netherlands
- Volunteers
- 26 people
- Sponsor
- The Netherlands Cancer Institute
Prostate Cancer
CART-PSMA Cells for Advanced Prostate Cancer
This is a single center, open-label phase 1 study to assess the safety and feasibility of PSMA-specific CAR modified autologous T cells (CART-PSMA cells) in patients with advanced prostate cancer.
- Trial name
- NCT05656573
- Testing
- CART-PSMA cells
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Nova Therapeutics LLC
Prostate Cancer
Experiment to Assess Preferences for Novel Hormonal Therapy and Androgen-deprivation Therapy in Prostate Cancer Patients
The purpose of this study is to quantify the preferences for novel hormonal therapy (NHT) +/- androgen-deprivation therapy (ADT) vs ADT monotherapy among patients with non-metastatic hormone-sensitive prostate cancer (PC) in the…
- Trial name
- NCT06500741
- Testing
- No Intervention
- Where
- United States
- Volunteers
- 374 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Prostate Cancer
Evaluation of Fapi-pet in Prostate Cancer.
The investigators explore the biodistribution of FAPI-PET expression in primary high-risk prostate cancer in men undergoing RALP and eLND and in men with metastatic PCa about to start next generation antiandrogen.
- Trial name
- FAPIPETPCA (NCT05192694)
- Testing
- Computed tomography
- Where
- Finland
- Volunteers
- 40 people
- Sponsor
- Helsinki University Central Hospital
Prostate Adenocarcinoma
Mild Hypofractionation With Proton Therapy or IMRT for Intermediate-Risk Prostate Cancer
This is a study to first establish feasibility of the study and then to register the treatment data of adult patients with a diagnosis of intermediate risk of prostate cancer presenting for definitive radiation treatment with…
- Trial name
- NCT01352429
- Testing
- Proton Therapy, IMRT
- Where
- 2 sites in United States
- Volunteers
- 303 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Urologic Cancer, Biochemical Recurrence of Malignant Neoplasm of Prostate
SRT in Combination With Pembrolizumab in Patients With Recurrent Prostate Cancer After Radical Prostatectomy
To evaluate the efficacy and safety of a pembrolizumab therapy of pembrolizumab in combination with standard salvage radiation therapy (SRT) in patients with biochemical recurrence (BCR) of prostate-specific antigen (PSA)…
- Trial name
- Pembro-SRT (NCT04931979)
- Testing
- Pembrolizumab Injection [Keytruda], Salvage Radiation Therapy (SRT)
- Where
- Germany
- Volunteers
- 49 people
- Sponsor
- Prof. Dr. med. Christian Gratzke
Prostate Cancer, Metabolic Syndrome
MRI Substudy; Metabolic Changes Due to Iatrogenic Hypogonadism
The purpose of this study is to investigate if androgen deprivation therapy in men with prostate cancer increases hepatic fat content and changes visceral/subcutaneous fat distribution.
- Conditions
- Prostate Cancer, Metabolic Syndrome, Hypogonadism, Fatty Liver
- Trial name
- NCT02102646
- Testing
- Triptorelin, Orchiectomy
- Where
- Denmark
- Volunteers
- 31 people
- Sponsor
- Herlev Hospital
Precancerous/Nonmalignant Condition, Prostate Cancer
Calcitriol in Preventing Prostate Cancer in Patients With Prostatic Intraepithelial Neoplasia
RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming, growing, or coming back. The use of calcitriol may prevent prostate cancer.
- Trial name
- NCT00118066
- Testing
- calcitriol, observation
- Where
- 5 sites in United States
- Volunteers
- 12 people
- Sponsor
- Rutgers, The State University of New Jersey
Prostate Cancer
Transdermal Estradiol and Exercise in Mitigating Adverse Effects of Androgen Deprivation Therapy for Prostate Cancer Radiation Therapy
The goal of the clinical trial is to find out whether transdermal estradiol will reduce the adverse effects of androgen deprivation therapy in prostate cancer patients.
- Trial name
- ESTRACISE (NCT06271551)
- Testing
- Transdermal estrogen, Active Comparator: Androgen deprivation therapy, Resistance training
- Volunteers
- 310 people
- Sponsor
- Central Finland Hospital District
Castration-Resistant Prostatic Neoplasms
A Study of Cetrelimab (JNJ-63723283), a Programmed Cell Death Receptor-1 (PD-1) Inhibitor, Administered in Combination With Apalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer
The purpose of this study is to evaluate the safety of the combination of cetrelimab, with apalutamide and to define a population of participants with metastatic castration-resistant prostate cancer (mCRPC) who respond to…
- Trial name
- NCT03551782
- Testing
- Cetrelimab 480 mg, Apalutamide 240 mg
- Where
- 34 sites in United States, Belgium and 5 more
- Volunteers
- 33 people
- Sponsor
- Janssen Research & Development, LLC
Prostate Cancer, Radiotherapy Side Effect
PROstate CAncer Radiotherapy - Bowel Quality of Life (PROCAR-BQ)
This is a prospective pilot study to evaluate the mean increase of bowel symptoms after pelvic radiotherapy (RT) in prostate cancer (PCa) patient using the validated \& newly translated EORTC-QLQ PRT20 module.
- Conditions
- Prostate Cancer, Radiotherapy Side Effect, Bowel Dysfunction, Quality of Life
- Trial name
- PROCAR-BQ (NCT05880446)
- Testing
- Bowel symptoms & QoL assessment
- Where
- Belgium
- Volunteers
- 41 people
- Sponsor
- Jules Bordet Institute
Prostate Cancer
Early Assessment of Treatment Response Using Functional Diffusion Mapping
This study will evaluate the feasibility of identifying changes in diffusion MRI characteristics of bone that correlates with response to therapy in men with metastatic prostate cancer.
- Trial name
- NCT02064283
- Testing
- Diffusion MRI
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Michigan Rogel Cancer Center
Health Status Unknown, Elevated PSA
Diagnosing Clinically Significant Prostate Cancer In African American and White Men With Elevated PSA
This randomized phase II trial studies how well systematic random biopsy or magnetic resonance imaging (MRI)-ultrasound image (US) fusion biopsy work in diagnosing prostate cancer in patients with elevated prostate specific…
- Trial name
- NCT03234556
- Testing
- Biopsy of Prostate, Laboratory Biomarker Analysis, Magnetic Resonance Imaging
- Where
- 4 sites in United States
- Volunteers
- 288 people
- Sponsor
- University of Southern California
CRPC, Prostate Cancer
A Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension), Administered to Patients With Metastatic Castration-Resistant Prostate Cancer
The purpose of this study is to evaluate the efficacy and safety BIND-014 in patients with metastatic castration-resistant prostate cancer (mCRPC).
- Trial name
- NCT01812746
- Testing
- BIND-014
- Where
- 8 sites in United States
- Volunteers
- 42 people
- Sponsor
- BIND Therapeutics
Hormone-Resistant Prostate Cancer, Metastatic Prostatic Adenocarcinoma
Phenelzine Sulfate and Docetaxel in Treating Patients With Prostate Cancer With Progressive Disease After First-Line Therapy With Docetaxel
This phase II trial studies how well giving phenelzine sulfate together with docetaxel works in treating patients with prostate cancer that is growing, spreading, or getting worse after first-line therapy with docetaxel.
- Conditions
- Hormone-Resistant Prostate Cancer, Metastatic Prostatic Adenocarcinoma, Prostate Adenocarcinoma, Recurrent Prostate Carcinoma
- Trial name
- NCT01253642
- Testing
- Biopsy of Prostate, Docetaxel, Laboratory Biomarker Analysis
- Where
- 3 sites in United States
- Volunteers
- 11 people
- Sponsor
- OHSU Knight Cancer Institute
Prostate Cancer
Adoptive Transfer of Autologous T Cells Targeted to Prostate Specific Membrane Antigen (PSMA) for the Treatment of Castrate Metastatic Prostate Cancer (CMPC)
This is a phase I study which will test the safety of different doses of the patients own immune cells which have been changed to help recognize and destroy the cancer cells.
- Trial name
- NCT01140373
- Testing
- engineered autologous T cells, cyclophosphamide
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Very High Risk Prostate Carcinoma
Neoadjuvant Lu-PSMA Radioligand Therapy and Ipilimumab in Men With Very High-risk Prostate Cancer
A randomized, open-label Phase I/II study of neoadjuvant treatment with [177Lu]Lu-PSMA-617 radioligandtherapy (LuPSMA) with or without Ipilimumab in participants with very high-risk prostate cancer who are candidates for Radical…
- Trial name
- NEPI (NCT06388369)
- Testing
- [177Lu]Lu-PSMA-617, Ipilimumab
- Where
- Germany
- Volunteers
- 1 people
- Sponsor
- University Hospital, Essen
Pancreas Cancer, Lung Cancer
Stereotactic Magnetic Resonance Guided Radiation Therapy
This is a master prospective Phase I-II trial evaluating feasibility and efficacy of stereotactic magnetic resonance (MR) guided adaptive radiation therapy (SMART) in patients with cancer.
- Conditions
- Pancreas Cancer, Lung Cancer, Renal Cancer, Adrenal Metastases
- Trial name
- NCT04115254
- Testing
- MR-guided Linac
- Where
- 2 sites in United States
- Volunteers
- 397 people
- Sponsor
- Dana-Farber Cancer Institute
Prostate Carcinoma
To Evaluate if Green Tea Can be Effective in Reducing the Progression of Prostate Cancer in Men on Close Monitoring
This phase II trial studies how well green tea catechins work in preventing progression of prostate cancer from a low risk stage to higher risk stages in men who are on active surveillance.
- Trial name
- NCT04597359
- Testing
- Quality-of-Life Assessment, Questionnaire Administration, Sinecatechins
- Where
- 353 sites in United States, Guam and 1 more
- Volunteers
- 360 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.